Security key
46489V302
Perspective Therapeutics, Inc. - Common Stock, $0.001 par value (CATX)
CUSIP: 46489V302
Q2 2024 13F Holders as of 30 Jun 2024
- Security type / class
- Equity / Common Stock, $0.001 par value
- Total 13F shares
- 38,531,736
- Total 13F value
- $384,149,816
- Share change
- +38,503,012
- SEC-reported price per share
- $9.97
- Number of holders
- 102
- Value change
- +$383,863,185
- Number of buys
- 100
- Shares outstanding
- 114,405,130
Holder snapshot
5 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q2 2024
Institutions
102
Top holders
10
CATX full security history
Ownership snapshot
Full 13F holder table
Perspective Therapeutics, Inc. SEC filings
Perspective Therapeutics, Inc. company facts
Broader feeds
Ownership snapshot
Top reported holders of CATX - Perspective Therapeutics, Inc. - Common Stock, $0.001 par value (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Lantheus Holdings, Inc.
Disclosed value leader
Lantheus Holdings, Inc.
Comparable rows
1/6
Latest evidence
15 May 2024
13D/G
3/4/5
Lead comparable stake: 10%
5 rows are not safely comparable across share classes.
13D/G row: Lantheus Holdings, Inc.
Quick read
Lantheus Holdings, Inc. leads the comparable SEC ownership view at 10%.
1 of 6 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Lantheus Holdings, Inc.'s linked filing trail.
Comparable ownership
Top 1
Lantheus Holdings, Inc.
10%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 6 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Lantheus Holdings, Inc. |
13D/G
|
10%
|
$35,465,590
11,440,513 shares
|
$0 | 15 May 2024 |
| Jennifer Streeter |
3/4/5
COO & VP of HR
|
—
class O/S missing
|
—
1,722,500 shares
|
— | 12 Jun 2023 |
| William Cavanagh |
3/4/5
Chief R&D Officer
|
—
class O/S missing
|
—
1,493,846 shares
|
— | 21 Jul 2022 |
| Michael W. McCormick |
3/4/5
Director
|
—
class O/S missing
|
—
1,124,615 shares
|
— | 21 Feb 2023 |
| Philip J. Vitale |
3/4/5
Director
|
—
class O/S missing
|
—
425,000 shares
|
— | 21 Jul 2022 |
| Alan Hoffmann |
3/4/5
Director
|
—
class O/S missing
|
—
424,615 shares
|
— | 21 Jul 2022 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q2 2024
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
102
Shares
38,531,736
Rows available
102
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q2 2024 vs Q1 2024 Across Filers
Q1 2024 holders
0
Q2 2024 holders
102
Holder diff
102
| Investor | Q1 2024 Shares | Q2 2024 Shares | Share Diff | Share Chg % | Q1 2024 value | Q2 2024 value | Value change | Value Chg % |
|---|